



Department of Neuroscience, Croatian Institute for Brain 
Research, University of Zagreb School of Medicine, Zagreb, 
Croatia 
gsimic@hiim.hr




Croat Med J. 2019;60:485-7 
https://doi.org/10.3325/cmj.2019.60.485
This issue of the Croatian Medical Journal (CMJ) features 
two articles on rare diseases: one dealing with primary bil-
iary cholangitis (1) and the other with muscular dystrophy 
and spinal muscular atrophy (SMA) (2). At the CMJ editorial 
board meeting, these articles have generated considerable 
discussions about problems regarding research and health 
policies on rare diseases, particularly in a relatively small 
country such as Croatia.
By definition, a rare disease affects fewer than one indi-
vidual in 2000 people in the general population. Howev-
er, as there are nearly 8000 rare diseases (some even with-
out a name), it turns out that these “rare” diseases affect 
more than 300 million people worldwide (about 6% of the 
world’s population). Rare diseases, however, take a dispro-
portionately high share of the health budget, estimated 
at about 20%. Some of them affect only a few individuals, 
while others affect hundreds of thousands. Regardless of 
whether a single rare disease affects millions or just one 
person, it has enormous medical and social implications, 
and its impact on the affected individuals and their fami-
lies is generally devastating. This is especially the case be-
cause over 50% of rare diseases affect children, almost half 
of whom die before the age of 10.
Since 2008, rare diseases have been a priority area for ac-
tion in EU public health programs (https://ec.europa.eu/
health/ph_threats/non_com/docs/rare_com_en.pdf ). In 
2011, the International Rare Diseases Research Consortium 
(http://www.irdirc.org/) was launched, with the ambitious 
goals of developing diagnostics for most rare diseases and 
new treatments for 200 of them by 2020.
Historically, rare diseases have become also known as or-
phan diseases because pharmaceutical companies were 
not interested in developing treatments for them. How-
ever, after much struggle by parents’ non-profit organiza-
tions (eg, Families of SMA, Cure SMA, among others), and 
through the SMA Treatment Acceleration Act, in 2009 SMA 
entered the list of top 50 medical priorities in the USA. Af-
ter a series of clinical trials, on December 23, 2016 these 
joint efforts finally resulted in the approval by the Food and 
Drug Administration of nusinersen (Spinraza), a medica-
tion for all types of SMA. This example shows how a deeper 
understanding of the genome and disease pathogenesis, 
combined with energetic involvement of families, may 
change clinical research and drug development. These ef-
forts could also pave the way for the replacement of larger 
classifications of common disorders with more precisely 
defined individual diseases based on genetic markers. Cur-
rently, an open-label study is under way to assess the effi-
cacy, safety, tolerability, and pharmacokinetics of multiple 
doses of nusinersen delivered intrathecally to patients with 
genetically diagnosed and presymptomatic SMA (https://
clinicaltrials.gov/ct2/show/NCT02386553), which is esti-
mated to be completed in 2025.
We know that certain disorders, including brain disorders, 
are inherited. This experiential knowledge has been con-
firmed by twin studies, but it is only with the emergence 
of big data and multi-omics studies (genomics, transcrip-
tomics, epigenomics, proteomics, metabolomics, etc) that 
diagnostic and therapeutic approaches have been refor-
mulated under the umbrella term of personalized medi-
cine. New omics technologies have not only contributed 
to a better molecular characterization of diseases, espe-
cially rare diseases, but have also provided a new level of 
understanding of the enormous complexity of disease 
mechanisms (3). To respond to this level of complexi-
ty, we will need novel approaches, particularly those 
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that better address the nonprotein coding regions of the 
genome (4) and its three-dimensional organization (5). Lin-
ear hypotheses for any given research proposal or biomed-
ical problem are no longer considered scientifically sound 
and have been increasingly replaced by machine learning 
and artificial intelligence (AI) algorithms. Nevertheless, al-
though it is perfectly clear that each patient differently re-
sponds to a drug or an intervention on the basis of his or 
her individual genetic and molecular characteristics, due to 
the high costs of personalized medicine, all public health 
systems are still promoting primarily a “one-size fits all” ap-
proach. Hopefully, once the challenges of big data integra-
tion and translation from basic to clinical research are over-
come, innovations based on personalized health care will 
be increasingly replacing old health care practices.
One of the main obstacles to a full implementation of per-
sonalized medicine is that knowledge of genetic under-
pinnings of a given disorder is insufficient to understand 
disease pathophysiology, symptomatology, and course. 
For example, amyotrophic lateral sclerosis (ALS) and fron-
totemporal dementia (FTD) have for many decades been 
considered separate diseases. However, some ALS patients 
had additional symptoms, such as cognitive decline. This 
was first associated with the TDP-43 gene, but today we 
know that TDP-43 neurodegenerative syndrome occurs 
across a spectrum of conditions from ALS to FTD, where-
as the expansion of the hexanucleotide repeat in the 
C9ORF72 gene may cause only ALS, only FTD, or combina-
tions of both (6). Therefore, it emerges that one gene can 
produce a similar clinical picture of both familial or spo-
radic disease, or may lead to the same syndrome or com-
bination of syndromes. Conversely, multiple genes and 
pathways may cause the same clinical syndrome of Parkin-
son’s disease (PD). For example, mutations in PARK2, PARK4, 
and PARK6 genes are linked to mitochondrial dysfunction, 
whereas Lewy body accumulation can cause dementia 
(https://www.medpace.com/rare-diseases-are-showing-
the-way-toward-precision-medicine-part-1/). The finding 
of an increased risk of PD in individuals with Gaucher’s dis-
ease compared with the general population led to the dis-
covery that mutations of GBA gene for lysosomal enzyme 
glucocerebrosidase are foundational in some patients with 
PD. Patients with GBA-associated parkinsonism exhibit 
varying parkinsonian phenotypes, an earlier age of onset, 
and more associated cognitive changes than patients with 
parkinsonism without GBA mutations (7).
These examples illustrate how a top-down approach 
to understand a disease, from signs and symptoms 
through anatomical and functional substrates to path-
ways, risk factors, and search for a final common pathway, 
has dramatically changed to include untargeted omics ap-
proaches combined with AI-driven pattern recognition 
and prediction. Instead of approaching single syndromes 
by searching for a common final pathway, every individ-
ual should be diagnosed and treated as having a separate 
disease. Such approach has the additional advantage that, 
based on biomarker findings (imaging, biochemical, or 
other), it is possible to detect the earliest changes in a pro-
dromal stage and treat a disorder before the clinical onset 
of symptoms.
In rare diseases, this has become a regular approach be-
cause these diseases are driven by a genetic mutation (over 
80% of rare diseases have a strong genetic background), 
which is the obvious treatment target. Beyond SMA treat-
ment, many more drugs for rare diseases were approved in 
2016, so that altogether 41% of all drug approvals for that 
year were for the treatment of rare diseases.
Unlike neurological disorders, and in spite of the strong 
evidence for heritability, there has been a much slower 
progress in psychiatric diseases such as schizophrenia and 
bipolar disorder. One of the main reasons is that genome- 
and epigenome-wide association studies on these dis-
eases have generally been very inconsistent. Loci involved 
in these diseases are often single nucleotide polymor-
phisms, and they do not correlate with a neuropathology, 
which is far less well-defined. Considering that schizophre-
nia is associated with over 3000 genes, its molecular basis 
is even more diverse than its symptomatic diversity. There-
fore, the understanding of its pathogenetic mechanisms 
requires the understanding the action of a large number of 
genes, including those of the neuroimmune system, their 
products, and regulatory elements, and those involved in 
neural crest cells migration and domestication (8), as well 
as the consequences of their overexpression and/or de-
creased expression in the context of brain development 
(9). In other words, the number of genes affecting behavior 
in schizophrenia is too large for us to make targeted thera-
pies. In addition, intervening in the brain has always been 
hindered by problems of drug delivery.
Recent breakthroughs in advanced gene and cell therapies 
have potentially provided the first treatments for some rare 
diseases. Some of these approvals were highly controver-
sial, as were their huge costs. However, it remains the case 
that over 90% of rare diseases lack an approved treatment 
(https://www.orpha.net/consor/cgi-bin/Drugs_Search.
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php?lng=EN). Human induced pluripotent stem cells and 
genome editing technology, particularly CRISPR/Cas, have 
been tremendous advances, quickly progressing toward 
clinical development, although not without ethical issues 
remaining to be resolved. While most of these develop-
ments are very encouraging, much remains to be done. 
In the years to come, the development of effective, safe, 
and affordable new treatments for rare diseases will re-
quire coordinated involvement of all relevant stakeholders, 
from patients and their families and associations to other 
funders, researchers, pharmaceutical companies, clinicians, 
and governments.
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